Relevant bibliographies by topics / High dose rate brachytherapy / Journal articles
To see the other types of publications on this topic, follow the link: High dose rate brachytherapy.

Journal articles on the topic 'High dose rate brachytherapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'High dose rate brachytherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Herskovic, Arnold M. "High dose rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 17 (January 1989): 106. http://dx.doi.org/10.1016/0360-3016(89)90619-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Petereit, Daniel G., and Jack F. Fowler. "High-dose-rate brachytherapy—." International Journal of Radiation Oncology*Biology*Physics 55, no. 5 (April 2003): 1159–61. http://dx.doi.org/10.1016/s0360-3016(02)04526-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Speiser, Burton L. "High dose rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 19 (January 1990): 115. http://dx.doi.org/10.1016/0360-3016(90)90638-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Speiser, Burton L. "High dose rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 21 (January 1991): 103. http://dx.doi.org/10.1016/0360-3016(91)90418-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Speiser, Burton L. "High dose rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 24 (January 1992): 110–11. http://dx.doi.org/10.1016/0360-3016(92)90115-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Speiser, Borton L. "High dose rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 27 (1993): 116. http://dx.doi.org/10.1016/0360-3016(93)90609-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Itami, Jun. "Modern development of high-dose-rate brachytherapy." Japanese Journal of Clinical Oncology 50, no. 5 (March 5, 2020): 490–501. http://dx.doi.org/10.1093/jjco/hyaa029.

Full text
Abstract:
Abstract Brachytherapy is an invasive therapy with placement of radiation source into or near the tumor. The difference between planning target volume and clinical target volume is minimal, and the dose out of the tumor reduces rapidly due to the inverse-square law. High-dose-rate brachytherapy enables three-dimensional image guidance, and currently, tumor dose as well as doses of the surrounding normal structures can be evaluated accurately. High-dose-rate brachytherapy is the utmost precision radiation therapy even surpassing carbon ion therapy. Biological disadvantages of high-dose rate have been overcome by the fractional irradiation. High-dose-rate brachytherapy is indispensable in the definitive radiation therapy of cervical cancer. Also in prostate cancer and breast cancer, high-dose-rate brachytherapy plays a significant role. Brachytherapy requires techniques and skills of radiation oncologists at the time of invasive placement of the radiation source into the tumor area. Education of young radiation oncologists is most urgent and important.
APA, Harvard, Vancouver, ISO, and other styles
8

Nag, Subir, and Kenneth S. Hu. "Intraoperative high-dose-rate brachytherapy." Surgical Oncology Clinics of North America 12, no. 4 (October 2003): 1079–97. http://dx.doi.org/10.1016/s1055-3207(03)00092-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Alberti, Winfried E. "Endobronchial high dose rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 25, no. 4 (March 1993): 753–55. http://dx.doi.org/10.1016/0360-3016(93)90024-p.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Martinez, Alvaro A., Jeffrey Demanes, Carlos Vargas, Lionel Schour, Michel Ghilezan, and Gary S. Gustafson. "High-Dose-Rate Prostate Brachytherapy." American Journal of Clinical Oncology 33, no. 5 (October 2010): 481–88. http://dx.doi.org/10.1097/coc.0b013e3181b9cd2f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Houdek, Pavel V., James G. Schwade, Xiaodong Wu, Vincent Pisciotta, Jeffrey A. Fiedler, Christopher F. Serago, Arnold M. Markoe, et al. "Dose determination in high dose-rate brachytherapy." International Journal of Radiation Oncology*Biology*Physics 24, no. 4 (January 1992): 795–801. http://dx.doi.org/10.1016/0360-3016(92)90731-v.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Houdek, Pavel V., James G. Schwade, Xiaodong Wu, Vincent Piscotta, Jeffrey A. Fiedler, Christopher F. Serago, Arnold M. Markoe, et al. "Dose Determination in High Dose-Rate Brachytherapy." Medical Dosimetry 18, no. 2 (1993): 85–86. http://dx.doi.org/10.1016/0958-3947(93)90040-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Tyree, W. C., H. Cardenes, M. Randall, and L. Papiez. "High-dose-rate brachytherapy for vaginal cancer: Learning from treatment complications." International Journal of Gynecologic Cancer 12, no. 1 (January 2002): 27–31. http://dx.doi.org/10.1136/ijgc-00009577-200201000-00005.

Full text
Abstract:
Abstract.Tyree WC, Cardenes H, Randall M, Papiez L. High-dose-rate brachytherapy for vaginal cancer: learning from treatment complications.Historically, early stage vaginal cancer has been treated with low-dose-rate (LDR) brachytherapy with or without external beam radiation therapy (EBRT). Complication rates have been low and treatment efficacious. Although high-dose-rate (HDR) brachytherapy has been used for cervical cancer in many countries for over a decade, only more recently has it been integrated into treatment plans for vaginal cancer. This paper describes three patients treated with HDR brachytherapy who experienced significant late effects. Given the very limited amount of literature regarding the use of HDR brachytherapy in vaginal cancer, this analysis potentially contributes to an understanding of treatment-related risk factors for complications among patients treated with this modality.A focused review of hospital and departmental treatment records was done on three patients treated with HDR brachytherapy. Abstracted information included clinical data, treatment parameters (technique, doses, volume, combinations with other treatments) and outcomes (local control, survival, early and late effects). A review of the available literature was also undertaken.All patients had significant complications. Although statistical correlations between treatment parameters and complications are impossible given the limited number of patients, this descriptive analysis suggests that vaginal length treated with HDR brachytherapy is a risk factor for early and late effects, that the distal vagina has a lower radiation tolerance than the upper vagina with HDR as in LDR, and that combining HDR with LDR as done in our experience carries a high risk of late toxicity.Integration of HDR brachytherapy techniques into treatment plans for early stage vaginal cancers must be done cautiously. The etiology of the significant side effects seen here is likely to be multifactorial. For users of HDR brachytherapy in vaginal cancer, there is a need to further refine and standardize treatment concepts and treatment delivery. Ideally this will be based on continued careful observation and reporting of both favorable and unfavorable outcomes and experiences.
APA, Harvard, Vancouver, ISO, and other styles
14

Miglierini, P., J. P. Malhaire, G. Goasduff, O. Miranda, and O. Pradier. "Cervix cancer brachytherapy: High dose rate." Cancer/Radiothérapie 18, no. 5-6 (October 2014): 452–57. http://dx.doi.org/10.1016/j.canrad.2014.06.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Ash, DV. "High Dose Rate Brachytherapy - A Textbook." British Journal of Cancer 72, no. 1 (July 1995): 252. http://dx.doi.org/10.1038/bjc.1995.315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Nag, S. "Remote controlled high dose rate brachytherapy." Critical Reviews in Oncology/Hematology 22, no. 2 (March 1996): 127–50. http://dx.doi.org/10.1016/1040-8428(95)00190-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Solodkiy, Vladimir, Andrey Pavlov, Aleksey Tsybulskiy, and Anton Ivashin. "LOW-DOSE-RATE OR HIGH-DOSE-RATE BRACHYTHERAPY IN COMBINATION WITH EXTERNAL BEAM RADIOTHERAPY FOR INTERMEDIATE AND HIGH-RISK PROSTATE CANCER." Problems in oncology 64, no. 1 (January 1, 2018): 79–83. http://dx.doi.org/10.37469/0507-3758-2018-64-1-79-83.

Full text
Abstract:
Introduction. One of the main problems of modem on-courology is treatment for prostate cancer of intermediate and high risk of progression. Modern radiotherapy in this category of patients has an advantage over surgical methods of treatment. One way to improve the effectiveness of radiotherapy is to escalate the dose in the prostate gland. For this purpose a combination of brachytherapy and remote radiotherapy is used. This combination allows increasing the dose of radiation, thereby providing better local control, reducing complications from neighboring organs. Purpose of the study. To conduct a comparative analysis of efficacy and safety of radical treatment of patients with prostate cancer at medium and high risk of progression using a combination of high and low dose rate brachytherapy with external beam radiotherapy. Materials and methods. 107 patients with prostate cancer of the group of medium and high risk of progression combined treatment (brachytherapy with external beam radiotherapy) was conducted. 53 patients underwent combined treatment (HDR-brachytherapy and external beam radiotherapy). 54 patients underwent combined treatment (LDR-brachytherapy and external beam radiotherapy). The observation period was 5 years. Conclusion. In a comparative analysis in groups of combined radiotherapy with the use of high-dose and low-dose-rate brachytherapy, the same effectiveness of immediate and long-term results of treatment was demonstrated. A significant reduction in early and late toxic reactions in patients with high-power brachytherapy has been demonstrated.
APA, Harvard, Vancouver, ISO, and other styles
18

Pos, Floris J., Simon Horenblas, Joos Lebesque, Luc Moonen, Christoph Schneider, Peter Sminia, and Harry Bartelink. "Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer." International Journal of Radiation Oncology*Biology*Physics 59, no. 3 (July 2004): 696–705. http://dx.doi.org/10.1016/j.ijrobp.2003.11.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Petera, Jiri, Renata Neumanová, Karel Odrazka, Martin Ondrak, and Egon Prochazka. "Perioperative Hyperfractionated High-Dose Rate Brachytherapy Combined with External Beam Radiotherapy in the Treatment of Soft Tissue Sarcomas." Tumori Journal 91, no. 4 (July 2005): 331–34. http://dx.doi.org/10.1177/030089160509100409.

Full text
Abstract:
Aims and background Low-dose rate brachytherapy alone or in combination with external beam radiotherapy represents a well-established adjuvant treatment in soft tissue sarcomas following surgical resection. The experience with high-dose radiotherapy in this indication is limited. The purpose of our study was an evaluation of the viability of perioperative hyperfractionated high-dose rate brachytherapy in combination with external beam radiotherapy for primary and recurrent soft tissue sarcomas. Patients and methods From February 1998 through June 2002, 10 adult patients with soft tissue sarcomas were treated by interstitial perioperative high-dose rate brachytherapy and external beam radiotherapy. TNM classification was pT2bpN0pM0 in 9 patients and pT1bpN0pM0 in 1 patient. Grade of differentiation was G1 (2 patients), G2 (n = 1), G3 (n = 5), G4 (n = 2). Surgical margins were negative in 7 cases, close in 2 cases and positive in 1 case. The tumor was localized in an extremity in all cases. Hyperfractionation 3 Gy twice daily at 10 mm from the plane of sources was used for brachytherapy, with total doses 18–30 Gy. The patients received external beam radiotheapy with doses 40–50 Gy after brachytherhapy. Follow-up periods were between 24–71 months (median, 46). Results Local control of the disease was achieved in all 10 patients. Distant metastases occurred in 2 cases. One patient was disease free after salvage surgery and chemotherapy, and one patient died of lung disease progression 14 months after brachytherapy. In one case, subcutaneous fistula occurred after radiotherapy and was cured by an excision. Six patients experienced grade 1 or 2 fibrosis and 1 case a mild peripheral neuropathy was recorded. Conclusions Our study on a small number of patients suggests that perioperative hyperfractionated high-dose rate brachytherapy with doses 8 × 3 Gy in combination with external beam radiotherapy 40–50 Gy is a promising method to achieve high biological doses in the postoperative radiotherapy of soft tissue sarcomas without severe late morbidity and warrants further research.
APA, Harvard, Vancouver, ISO, and other styles
20

Goyal, Manish K., T. S. Kehwar, Jayanand Manjhi, Jerry L. Barker, Bret H. Heintz, Kathleen L. Shide, and D. V. Rai. "Dosimetric evaluation of tandem-based cervical high-dose-rate brachytherapy treatment planning using American Brachytherapy Society 2011 recommendations." Journal of Radiotherapy in Practice 15, no. 3 (April 15, 2016): 283–89. http://dx.doi.org/10.1017/s1460396916000133.

Full text
Abstract:
AbstractPurposeThis study evaluated dosimetric parameters for cervical high-dose-rate (HDR) brachytherapy treatment using varying dose prescription methods.MethodsThis study includes 125 tandem-based cervical HDR brachytherapy treatment plans of 25 patients who received HDR brachytherapy. Delineation of high-risk clinical target volumes (HR-CTVs) and organ at risk were done on original computed tomographic images. The dose prescription point was defined as per International Commission in Radiation Units and Measurements Report Number 38 (ICRU-38), also redefined using American Brachytherapy Society (ABS) 2011 criteria. The coverage index (V100) for each HR-CTV was calculated using dose volume histogram parameters. A plot between HR-CTV and V100was plotted using the best-fit linear regression line (least-square fit analysis).ResultsMean prescribed dose to ICRU-38 Point A was 590·47±28·65 cGy, and to ABS Point A was 593·35±30·42 cGy. There was no statistically significant difference between planned ICRU-38 and calculated ABS Point A doses (p=0·23). The plot between HR-CTV and V100is well defined by the best-fit linear regression line with a correlation coefficient of 0·9519.ConclusionFor cervical HDR brachytherapy, dose prescription to an arbitrarily defined point (e.g., Point A) does not provide consistent coverage of HR-CTV. The difference in coverage between two dose prescription approaches increases with increasing CTV. Our ongoing work evaluates the dosimetric consequences of volumetric dose prescription approaches for these patients.
APA, Harvard, Vancouver, ISO, and other styles
21

Kandasamy, Saravanan, K. S. Reddy, Vivekanandan Nagarajan, Parthasarathy Vedasoundaram, and Gunaseelan Karunanidhi. "Inter-fraction variation in interstitial high-dose-rate brachytherapy." Journal of Radiotherapy in Practice 14, no. 2 (February 4, 2015): 143–51. http://dx.doi.org/10.1017/s1460396915000047.

Full text
Abstract:
AbstractAimTo evaluate the inter-fraction variation in interstitial high-dose-rate (HDR) brachytherapy. To assess the positional displacement of catheters during the fractions and the resultant impact on dosimetry.BackgroundAlthough brachytherapy continues to be a key cornerstone of cancer care, it is clear that treatment innovations are needed to build on this success and ensure that brachytherapy continues to provide quality care for patients. The dosimetric advantages offered by HDR brachytherapy to the tumour volume rely on catheter positions being accurately reproduced for all fractions of treatment.Materials and methodsA total of 66 patients treated over a period of 22 months were considered for this study. All the patients underwent computer tomography (CT) scan and three-dimensional treatment planning was carried out. Brachytherapy treatment was delivered by the HDR afterloading system. On completing the last fraction, CT scan was repeated and treatment re-planning was done. The variation in position of the implanted applicators and their impact on dosimetric parameters were analysed using both the plans.ResultsFor all breast-implant patients, the catheter displacement and D90dose to clinical target volume were <3 mm and 3%, respectively. The displacement for carcinoma of the tongue, carcinoma of the buccal mucosa, carcinoma of the floor of mouth, carcinoma of the cervix, soft-tissue sarcoma and carcinoma of the lip were comparatively high.ConclusionInter-fraction errors occur frequently in interstitial HDR brachytherapy. If no action is taken, it will result in a significant risk of geometrical miss and overdose to the organs at risk. It is not recommended to use a single plan to deliver all the fractions. Imaging is recommended before each fraction and decision on re-planning must be taken.
APA, Harvard, Vancouver, ISO, and other styles
22

Visser, Andries G., Gerard J. M. J. van den Aardweg, and Peter C. Levendag. "Pulsed dose rate and fractionated high dose rate brachytherapy: Choice of brachytherapy schedules to replace low dose rate treatments." International Journal of Radiation Oncology*Biology*Physics 34, no. 2 (January 1996): 497–505. http://dx.doi.org/10.1016/0360-3016(95)02054-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Orton, Colin G. "High dose rate versus low dose rate brachytherapy for gynecological cancer." Seminars in Radiation Oncology 3, no. 4 (October 1993): 232–39. http://dx.doi.org/10.1016/s1053-4296(05)80120-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Ghadjar, Pirus, Beat Bojaxhiu, Mathew Simcock, Dario Terribilini, Bernhard Isaak, Philipp Gut, Patrick Wolfensberger, et al. "High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer." International Journal of Radiation Oncology*Biology*Physics 83, no. 4 (July 2012): 1205–12. http://dx.doi.org/10.1016/j.ijrobp.2011.09.038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Burt, Paul A. "High dose rate brachytherapy in endobronchial tumours." Lung Cancer 18 (August 1997): 35. http://dx.doi.org/10.1016/s0169-5002(97)83879-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Demanes, D. Jeffrey, and Dennis R. Hill. "High-dose-rate Brachytherapy of Prostate Cancer." Oncology & Hematology Review (US), no. 02 (2007): 98. http://dx.doi.org/10.17925/ohr.2007.00.2.98.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Devic, Slobodan, Té Vuong, Belal Moftah, Michael Evans, Ervin B. Podgorsak, Emily Poon, and Frank Verhaegen. "Image-guided high dose rate endorectal brachytherapy." Medical Physics 34, no. 11 (October 26, 2007): 4451–58. http://dx.doi.org/10.1118/1.2795669.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Demanes, D. Jeffrey, and Dennis R. Hill. "High-dose-rate Brachytherapy of Prostate Cancer." European Oncology & Haematology 00, no. 02 (2007): 92. http://dx.doi.org/10.17925/eoh.2007.0.2.92.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Nanavati, P., J. Fanning, R. Hilgers, and D. Crawford. "High dose rate brachytherapy in endometrial cancer." International Journal of Radiation Oncology*Biology*Physics 24 (January 1992): 304. http://dx.doi.org/10.1016/0360-3016(92)90432-h.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Stitt, Judith Anne, Bruce R. Thomadsen, and Jack F. Fowler. "High-dose-rate brachytherapy for cervical carcinoma." International Journal of Radiation Oncology*Biology*Physics 24, no. 3 (January 1992): 574. http://dx.doi.org/10.1016/0360-3016(92)91080-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

YamazakI, H., K. Yoshida, Y. Yoshioka, K. Shimizutani, S. Furukawa, M. Koizumi, and K. Ogawa. "High dose rate brachytherapy for oral cancer." Journal of Radiation Research 54, no. 1 (November 23, 2012): 1–17. http://dx.doi.org/10.1093/jrr/rrs103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Hoskin, P. "High dose rate brachytherapy for prostate cancer." Cancer/Radiothérapie 12, no. 6-7 (November 2008): 512–14. http://dx.doi.org/10.1016/j.canrad.2008.07.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Fanning, J., P. J. Nanavati, and R. D. Hilgers. "High dose rate brachytherapy in endometrial cancer." Gynecologic Oncology 45, no. 1 (April 1992): 98. http://dx.doi.org/10.1016/0090-8258(92)90584-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Poder, Joel, Ryan L. Smith, Nikki Shelton, May Whitaker, Duncan Butler, and Annette Haworth. "High dose rate brachytherapy source measurement intercomparison." Australasian Physical & Engineering Sciences in Medicine 40, no. 2 (March 24, 2017): 377–83. http://dx.doi.org/10.1007/s13246-017-0542-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Lo, Theodore. "High Dose Rate Brachytherapy for Prostate Cancer." Brachytherapy 14 (May 2015): S96—S97. http://dx.doi.org/10.1016/j.brachy.2015.02.366.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Tien, Christopher Jason, Michael Butkus, John Stahl, Jack Qian, Zhe Chen, and Shari Damast. "Does Variable 192 Ir Dose Rate Affect Vaginal Toxicity in High-Dose-Rate Brachytherapy?" Brachytherapy 16, no. 3 (May 2017): S76—S77. http://dx.doi.org/10.1016/j.brachy.2017.04.139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Strom, Tobin Joel Crill, Alex Cruz, Nicholas Figura, Kushagra Shrinath, Kevin Nethers, Eric Albert Mellon, Daniel Celestino Fernandez, et al. "Health-related quality of life changes due to high-dose rate brachytherapy, low-dose rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 72. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.72.

Full text
Abstract:
72 Background: To compare urinary, bowel, and sexual health-related quality of life (HRQOL) changes due to high-dose rate (HDR) brachytherapy, low-dose rate (LDR) brachytherapy, or intensity modulated radiation therapy (IMRT) monotherapy for prostate cancer. Methods: Between January 2002 and September 2013, 413 low-risk or favorable intermediate-risk prostate cancer patients were treated with HDR brachytherapy monotherapy to 2,700-2,800 cGy in two fractions (n=85), iodine-125 LDR brachytherapy monotherapy to 14,500 cGy in one fraction (n=249), or IMRT monotherapy to 7,400-8,100 cGy in 37-45 fractions (n=79) without pelvic lymph node irradiation. No androgen deprivation therapy was given. Patients used an International Prostate Symptoms Score questionnaire, an Expanded Prostate cancer Index Composite-26 bowel questionnaire, and a Sexual Health Inventory for Men questionnaire to assess their urinary, bowel, and sexual HRQOL, respectively, pre-treatment and at 1, 3, 6, 9, 12, and 18 months post-treatment. Results: Median follow-up was 32 months. HDR brachytherapy and IMRT patients had significantly less deterioration in their urinary HRQOL than LDR brachytherapy patients at 1 and 3 months post-irradiation. The only significant decrease in bowel HRQOL between the groups was seen 18 months following treatment, at which point IMRT patients had a slight, but significant, deterioration in their bowel HRQOL compared with HDR and LDR brachytherapy patients. HDR brachytherapy patients had worse sexual HRQOL than both LDR brachytherapy and IMRT patients following treatment. Conclusions: IMRT and HDR brachytherapy cause less severe acute worsening of urinary HRQOL than LDR brachytherapy. However, IMRT causes a slight, but significant, worsening of bowel HRQOL compared with HDR and LDR brachytherapy.
APA, Harvard, Vancouver, ISO, and other styles
38

De Cicco, Luigi, Barbara Vischioni, Andrea Vavassori, Federica Gherardi, Barbara Alicja Jereczek-Fossa, Roberta Lazzari, Federica Cattani, et al. "Postoperative management of keloids: Low-dose-rate and high-dose-rate brachytherapy." Brachytherapy 13, no. 5 (September 2014): 508–13. http://dx.doi.org/10.1016/j.brachy.2014.01.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Korpics, Mark, Amishi Bajaj, Michael Mysz, Brendan Martin, Murat Surucu, John Roeske, William Small, Matthew Harkenrider, and Abhishek Solanki. "Comparing Low Dose Rate and High Dose Rate Prostate Brachytherapy Implant Dosimetry." Brachytherapy 16, no. 3 (May 2017): S113—S114. http://dx.doi.org/10.1016/j.brachy.2017.04.221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Park, Ju-Kyeong, Seung-Hun Lee, Seok-Yong Cha, Yang-Su Kim, and Sun-Young Lee. "Availability and Reproducibility Evaluation of High-dose-rate Intraluminal Brachytherapy for Unresectable Recurrent Cholangiocarcinoma." Journal of the Korean Society of Radiology 6, no. 2 (April 30, 2012): 151–57. http://dx.doi.org/10.7742/jksr.2012.6.2.151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Nevelsky, Alexander, Raquel Bar-Deroma, Gökçen Yildrim Çokal, Edward Rosenblatt, and Abraham Kuten. "Definition of vaginal doses in intrauterine high–dose-rate brachytherapy." Brachytherapy 3, no. 2 (January 2004): 101–5. http://dx.doi.org/10.1016/j.brachy.2004.05.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Yagudaev, D. M., Z. A. Kadyrov, M. R. Kalinin, V. A. Bezhenar, and N. A. Kalyagina. "Salvage high-dose-rate brachytherapy for local recurrence of prostate cancer." Cancer Urology 14, no. 2 (July 7, 2018): 171–75. http://dx.doi.org/10.17650/1726-9776-2018-14-2-171-175.

Full text
Abstract:
The article describes a successful experience of using high-dose rate brachytherapy (192Ir) in patients with local recurrence of hormone-resistant prostate cancer. High-dose rate brachytherapy allowed to achieve local biochemical control of prostate cancer without toxicity to pelvic organs, thus, maintaining the quality of life.
APA, Harvard, Vancouver, ISO, and other styles
43

Yamada, Yoshiya, Leland Rogers, D. Jeffrey Demanes, Gerard Morton, Bradley R. Prestidge, Jean Pouliot, Gil'ad N. Cohen, Marco Zaider, Mihai Ghilezan, and I.-Chow Hsu. "American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy." Brachytherapy 11, no. 1 (January 2012): 20–32. http://dx.doi.org/10.1016/j.brachy.2011.09.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Lloyd, S., K. M. Alektiar, S. Nag, Y. J. Huang, C. L. Deufel, F. Mourtada, and D. K. Gaffney. "Intraoperative high-dose-rate brachytherapy: An American Brachytherapy Society consensus report." Brachytherapy 16, no. 3 (May 2017): 446–65. http://dx.doi.org/10.1016/j.brachy.2017.01.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Kumar, Pavnesh, D. N. Sharma, G. K. Rath, P. K. Julka, Sunesh Kumar Jain, K. P. Haresh, and Subhash Gupta. "Pulsed-Dose-Rate vs. High-Dose-Brachytherapy in Cervical Carcinoma." Brachytherapy 12 (March 2013): S26. http://dx.doi.org/10.1016/j.brachy.2013.01.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

NOSE, Takayuki, Masahiko KOIZUMI, Kinji NISHIYAMA, Ken YOSHIDA, and Toshihiko INOUE. "HIGH DOSE RATE INTERSTITIAL BRACHYTHERAPY FOR OROPHARYNX CANCER." Japanese jornal of Head and Neck Cancer 28, no. 1 (2002): 198–204. http://dx.doi.org/10.5981/jjhnc1974.28.198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Deger, S. "High Dose Rate Brachytherapy of Localized Prostate Cancer." European Urology 41, no. 4 (April 2002): 420–26. http://dx.doi.org/10.1016/s0302-2838(02)00016-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Deger, S., D. Böhmer, J. Roigas, I. Türk, V. Budach, and S. Loening. "High dose rate brachytherapy of localized prostate cancer." European Urology Supplements 2, no. 1 (February 2003): 133. http://dx.doi.org/10.1016/s1569-9056(03)80526-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Schumer, W., S. Wallace, T. Wong, G. Quong, and M. Geso. "Dosimetry errors in endovascular high-dose-rate brachytherapy." Medical Dosimetry 25, no. 4 (December 2000): 225–29. http://dx.doi.org/10.1016/s0958-3947(00)00052-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Wong, Eric, Stephen Lam, Clive Grafton, Frances Wong, James Morris, Michael McKenzie, Karen Goddard, and Kenneth Yuen. "High-Dose Rate Brachytherapy for Obstructive Bronchial Tumors." Journal of Bronchology 1, no. 2 (April 1994): 99–104. http://dx.doi.org/10.1097/00128594-199404000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'High dose rate brachytherapy' for other source types:
Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography